Eli Lilly

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

UK spurs prescribing of obesity jab Mounjaro with GP bonus

Doctors in the UK will be given thousands of pounds in bonus payments from April for prescribing Eli Lilly's weight-loss drug Mounjaro.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Cartoon graphic of a woman with glasses holding thought bubbles in the palm of either hand, one with a check and one with a cross

Head-to-head trial dents Novo Nordisk's obesity hopes

Novo Nordisk slumps as its two-drug combination for weight loss, CagriSema, performs less well than Eli Lilly's rival Zepbound in a comparative trial.

News

Kailera, Hengrui stake claim to oral weight loss category

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

News

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

In its second major deal in two days, Eli Lilly has reached an agreement to buy in vivo CAR-T developer Orna Therapeutics for up to $2.4bn.

Astellas bets on Vir cancer drug, and other licensing deals

UK spurs prescribing of obesity jab Mounjaro with GP bonus

FDA clears first all-oral combo for first-line CLL treatment

Head-to-head trial dents Novo Nordisk's obesity hopes

Kailera, Hengrui stake claim to oral weight loss category

Lilly strikes again, buying CAR-T firm Orna for $2.4bn

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks